Article ; Online: Implications of DNA damage repair alterations for the management of prostate cancer.
2022 Volume 32, Issue 3, Page(s) 302–310
Abstract: Purpose of review: In this review, we summarize the prevalence of alterations in DNA damage repair (DDR) genes in prostate cancer, their clinical significance, the therapeutic strategies developed to take advantage of the impaired tumour ability to ... ...
Abstract | Purpose of review: In this review, we summarize the prevalence of alterations in DNA damage repair (DDR) genes in prostate cancer, their clinical significance, the therapeutic strategies developed to take advantage of the impaired tumour ability to repair DNA and the diagnostic approaches available to identify patients likely to benefit from DDR-targeting agents. Recent findings: DDR alterations are more frequent in metastatic than in localized prostate cancer and some of them associate with aggressive disease whereas the significance of others remain unclear. The most appropriate management approach for DDR-defective prostate cancer patients is unknown. Clinical trials have demonstrated the efficacy of different poly-ADP ribose polymerase inhibitors (PARPi) to treat metastatic castration-resistant prostate cancer patients with BRCA1/2 alterations, although there may be other DDR alterations that sensitize patients to these drugs. Multiple strategies to target DDR defects are being investigated, including PARPi in combination, platinum-based chemotherapy and immunotherapy, both in earlier and late disease stages. Optimization of molecular testing is paramount for the implementation of precision oncology in prostate cancer. Summary: Certain DDR defects present in prostate cancer have prognostic and therapeutic implications whereas the significance of other DDR alterations is yet to be elucidated. |
---|---|
MeSH term(s) | DNA Damage ; DNA Repair ; Humans ; Male ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; Precision Medicine ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/genetics |
Chemical Substances | Poly(ADP-ribose) Polymerase Inhibitors |
Language | English |
Publishing date | 2022-03-09 |
Publishing country | United States |
Document type | Journal Article ; Review ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, Non-U.S. Gov't |
ZDB-ID | 1091792-5 |
ISSN | 1473-6586 ; 0963-0643 |
ISSN (online) | 1473-6586 |
ISSN | 0963-0643 |
DOI | 10.1097/MOU.0000000000000983 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 3345: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.